Shows
GRACEcast - Discussions with the Global Resource for Advancing Cancer EducationGRACECast - LCVL - H. Jack West MD - Can ALK inhibitors treat and prevent brain metastasesDr. Howard Jack West discusses ALK Rearrangement-Positive NSCLC and if ALK inhibitors treat and prevent brain metastases?2021-03-1207 min
GRACEcastPanel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and WestDrs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.2016-01-1026 min
GRACEcastQuestions & Answers with Drs. Pardoll, Hellmann, and Luke; Moderated by Dr. WestImmunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.2014-12-3117 minGRACEcastQuestions & Answers with Bonnie Addario and Craig Uthe; Moderated by Dr. Jack WestAcquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.2014-11-0424 minGRACEcastQuestions & Answers with Drs. Blumenthal and Pennell; Moderated by Dr. WestAcquired Resistance Forum Video #7: Speakers from videos #5 and #6 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.2014-10-1916 minGRACEcastQuestions & Answers with Drs. Riely, Weiss and Sequist; Moderated by Dr. WestAcquired Resistance Forum Video #4: The first three speakers at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.2014-10-1229 min
GRACEcast ALL Subjects audio and videoDoes Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.2014-06-1209 minGRACEcast Lung Cancer VideoDoes Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.2014-06-1209 min
GRACEcast Head and Neck Cancer AudioHPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly2013-07-2207 minGRACEcast ALL Subjects audio and videoHPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly2013-07-2207 min
GRACEcast ALL Subjects audio and videoIs there a place for maintenance therapy in extensive stage NSCLC?Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.2013-07-0404 minGRACEcast Lung Cancer VideoIs there a place for maintenance therapy in extensive stage NSCLC?Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.2013-07-0404 min
GRACEcast ALL Subjects audio and videoHow should we integrate new immunotherapies into treatment strategies for lung cancer?Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.2013-07-0404 minGRACEcast Lung Cancer VideoHow should we integrate new immunotherapies into treatment strategies for lung cancer?Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.2013-07-0404 min
GRACEcast ALL Subjects audio and videoHow do we approach acquired resistance to targeted therapies in lung cancer?Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.2013-07-0405 minGRACEcast Lung Cancer VideoHow do we approach acquired resistance to targeted therapies in lung cancer?Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.2013-07-0405 min
GRACEcast ALL Subjects audio and videoWhat have we learned from the START trial of immunotherapy in locally advanced NSCLC?Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.2013-07-0402 minGRACEcast Lung Cancer VideoWhat have we learned from the START trial of immunotherapy in locally advanced NSCLC?Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.2013-07-0402 min
GRACEcast ALL Subjects audio and videoCan we target KRAS effectively in advanced NSCLC?Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.2013-07-0204 minGRACEcast Lung Cancer VideoCan we target KRAS effectively in advanced NSCLC?Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.2013-07-0204 min
GRACEcast Lung Cancer VideoCould BRAF be a new target in NSCLC?Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.2013-06-2704 minGRACEcast ALL Subjects audio and videoCould BRAF be a new target in NSCLC?Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.2013-06-2704 min
GRACEcast Lung Cancer VideoCan we harness our immune system to fight NSCLC?Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.2013-06-1908 minGRACEcast ALL Subjects audio and videoCan we harness our immune system to fight NSCLC?Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.2013-06-1908 min
GRACEcast Lung Cancer VideoCan addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.2013-06-1906 minGRACEcast ALL Subjects audio and videoCan addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.2013-06-1906 min
GRACEcast Lung Cancer VideoIs there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.2013-06-1512 minGRACEcast ALL Subjects audio and videoIs there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.2013-06-1512 min
GRACEcast Lung Cancer VideoDo you need Avastin in first line and maintenance therapy in advanced NSCLC?Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta. 2013-06-1306 minGRACEcast ALL Subjects audio and videoDo you need Avastin in first line and maintenance therapy in advanced NSCLC?Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta. 2013-06-1306 min
GRACEcast Lung Cancer VideoCan we predict which patients will benefit from Tarceva based on a blood test?Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.2013-06-1207 minGRACEcast ALL Subjects audio and videoCan we predict which patients will benefit from Tarceva based on a blood test?Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.2013-06-1207 min
GRACEcast Lung Cancer VideoIs there a role for molecular markers predicting the best chemotherapy to use in lung cancer?Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).2013-06-1005 minGRACEcast ALL Subjects audio and videoIs there a role for molecular markers predicting the best chemotherapy to use in lung cancer?Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).2013-06-1005 min
GRACEcast Lung Cancer VideoIs it possible to test for biomarkers in lung cancer on a national scale?Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).2013-06-0705 minGRACEcast ALL Subjects audio and videoIs it possible to test for biomarkers in lung cancer on a national scale?Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).2013-06-0705 min
GRACEcast ALL Subjects audio and videoGRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, CanadaDr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.2013-05-1702 minGRACEcast Lung Cancer VideoGRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, CanadaDr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.2013-05-1702 min
GRACEcast Lung Cancer VideoCase in Point: How Should We Approach Someone with a Rare EGFR Mutation?Dr. Jack West describes recent information on the probability that someone with a rare EGFR mutation on exon 20, rather than a more common "activating" mutations on exon 19 or 21, will benefit from an oral EGFR inhibitor vs. standard chemotherapy.2013-02-1306 min
GRACEcast Lung Cancer VideoCase in Point: Recommendation for Adjuvant Chemotherapy for Lung Cancer Based on High Risk Tumor FeaturesDr. Jack West describes the factors that contribute to a recommendation for or against post-operative (adjuvant) chemotherapy for a patient with resected early stage non-small cell lung cancer.2013-02-1204 min
GRACEcast Radiation Oncology VideoCan we safely combine Tarceva with brain radiation for lung cancer with brain radiation?Dr. Jack West describes a case series that illustrates the safety of giving whole brain radiation along with concurrent Tarceva (erlotinib) for patients with lung cancer and brain metastases.2013-02-0803 min
GRACEcast Lung Cancer VideoIs there a new, promising option for people with the most common mutation seen in lung cancer?Dr. Jack West reviews the encouraging results with selumetinib, a MEK inhibitor, in combination with chemotherapy for patients with advanced NSCLC and a KRAS mutation, the most common molecular marker seen in lung cancer. 2013-01-2605 min
GRACEcast Lung Cancer VideoA High Profile Failure for Stimuvax: Lessons Learned and Future Prospects for ImmunotherapyDr. Jack West offers thoughts on the disappointing negative results of the START trial with the immunotherapy Stimuvax, and what this might mean as we anticipate the results of future trials of other immunotherapies moving forward in clinical trials in lung cancer.2013-01-0807 min
GRACEcast Lung Cancer VideoWhat is the Biology of a Mixed Response in Lung Cancer?Dr. Jack West discusses the likely biological underpinnings of a mixed response to treatment for advanced lung cancer and the potential utility of multiple biopsies to learn more about biological changes over time and in different tumor areas.2013-01-0505 min
GRACEcast Cancer 101 VideoThanks so much for your support in 2012: Here's to a great 2013!Dr. Jack West thanks the GRACE community for their generous support in our recent Annual Appeal and offers his wishes for a happy and healthy 2013.2013-01-0303 min
GRACEcast Lung Cancer VideoWhat Should We Do for a "Mixed Response" to Lung Cancer Treatment?Dr. Jack West describes what a mixed response is and how it can be interpreted and managed for advanced lung cancer.2013-01-0105 min
GRACEcast Lung Cancer VideoThe more you seek, the more you findDr. Jack West describes his evolving perspective on the yield of testing for molecular markers, which is leading him to become more optimistic about testing a broader range of people with NSCLC.2012-12-2706 min
GRACEcast Cancer 101 VideoHappy Holidays from Dr West and GRACEDr. Jack West wishes the cancer community a happy holiday season from GRACE.2012-12-2502 min
GRACEcast Cancer 101 VideoUsing Telemedicine to Deliver Optimal Subspecialty Care Across Healthcare NetworksDr. Jack West describes a potentially efficient way to improve delivery of increasingly specialized care to broad geographic areas by collaboration of healthcare network teams using telemedicine solutions currently available.2012-12-1905 min
GRACEcast Cancer 101 VideoDo we need to do repeat biopsies with disease progression?Dr. Jack West discusses the pros and cons of repeat biopsies of tumors in the setting of "acquired resistance" to targeted therapies, with a specific consideration of whether this should be considered a standard of care.2012-12-1403 min
GRACEcast Cancer 101 VideoWill your oncologist be a computer algorithm?Dr. Jack West reviews the limitations of artificial intelligence applied to clinical decision-making in complex cases in oncology, and why Dr. Watson won't necessarily become the perfect oncologist.2012-12-1204 min
GRACEcast Lung Cancer VideoWhich patients with advanced lung cancer should potentially receive local therapy?Dr. Jack West reviews what situations would make a "local" treatment like radiation appropriate in a situation where a patient has known advanced/metastatic lung cancer. 2012-12-0605 min
GRACEcast Radiation Oncology VideoIs there an alternative to brain radiation for patients with several brain metastases?Dr. Jack West reviews a case that illustrates the potential option of systemic therapy for brain metastases before initiating whole brain radiation.2012-12-0505 min
GRACEcast Lung Cancer VideoPerhaps Rash SHOULD be a Critical Factor in Clarifying Who Benefits from an EGFR Inhibitor: The TOPICAL StudyDr. H. Jack West reviews the TOPICAL study of Tarceva vs. placebo for marginal and poor PS patients with advanced NSCLC, which showed a clearly superior outcome with Tarceva in patients who developed a rash vs. those who don't.2012-11-2506 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 6: Moving Radiation Developments into Metastatic Lung Cancer (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews the rationale and feasibility of using focal radiation in the setting of metastatic lung cancer.2012-11-2505 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 6: Moving Radiation Developments into Metastatic Lung Cancer (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews the rationale and feasibility of using focal radiation in the setting of metastatic lung cancer.2012-11-2505 min
GRACEcast Lung Cancer VideoWhy is Chemotherapy Recommended for Most Patients with NSCLC, Even with Earlier Stage Disease?Dr. H. Jack West, medical oncologist from Swedish Cancer Institute in Seattle, WA, reviews the rationale for giving chemotherapy to patients with NSCLC even when it appears that the cancer is limited to the chest.2012-11-2302 min
GRACEcast Lung Cancer VideoHow Should We Treat Locally Advanced Non-Small Cell Lung Cancer?Dr. H. Jack West, medical oncologist from Swedish Cancer Institute in Seattle, WA, reviews the general principles of treating locally advanced non-small cell lung cancer (NSCLC).2012-11-1804 min
GRACEcast Cancer 101 VideoIntro to Casual Video GRACEcasts UncutDr. H. Jack West describes the new format of presenting cancer information in brief, more casual video-based format.2012-11-1602 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 5: New Techniques (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes new technologies that are improving the accuracy and safety of radiation for stage non-small cell lung cancer (NSCLC).2012-11-1510 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 5: New Techniques (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes new technologies that are improving the accuracy and safety of radiation for stage non-small cell lung cancer (NSCLC).2012-11-1510 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 4: Defining a Role for SBRT (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, covers the benefits and limitations of stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC).2012-11-0806 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 4: Defining a Role for SBRT (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, covers the benefits and limitations of stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC).2012-11-0806 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 3: Recent Successes and Open Questions (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews recent successful experiences with stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer and reviews several open questions about this strategy.2012-11-0506 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 3: Recent Successes and Open Questions (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews recent successful experiences with stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer and reviews several open questions about this strategy.2012-11-0506 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 2: The Rationale for Stereotactic Body Radiation Therapy, by Dr. Vivek Mehta (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes the ways to modulate the efficacy of radiation and explains why stereotactic body radiation therapy (SBRT) may be particularly effective for early lung cancer.2012-11-0109 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 2: The Rationale for Stereotactic Body Radiation Therapy, by Dr. Vivek Mehta (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes the ways to modulate the efficacy of radiation and explains why stereotactic body radiation therapy (SBRT) may be particularly effective for early lung cancer.2012-11-0109 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 1: A Historical Perspective, by Dr. Vivek Mehta (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, provides a historical perspective of radiation therapy as it transitions to a more targeted treatment approach.2012-10-2810 min
GRACEcast Radiation Oncology VideoGRACEcast Feeds Moving (video)The GRACEcast feeds on iTunes are moving!2012-03-1401 min
GRACEcast Lung Cancer AudioShould Surgery be Considered for Very Limited Small Cell Lung Cancer? (audio)Dr. Howard (Jack) West, medical oncologist, President & CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).2010-03-3124 min
GRACEcast Lung Cancer VideoShould Surgery be Considered for Very Limited Small Cell Lung Cancer? (video)Dr. Howard (Jack) West, medical oncologist, President & CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).2010-03-3124 minGRACEcast Lung Cancer AudioThought Leader Round Table: Drs Laskin and Sandler, Part 2 (audio)Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on first line chemo standards and the transition to maintenance therapy.2010-01-1209 min
GRACEcast Lung Cancer VideoThought Leader Round Table: Drs Laskin and Sandler, Part 2 (video)Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on first line chemo standards and the transition to maintenance therapy.2010-01-1209 minGRACEcast Lung Cancer AudioThought Leader Round Table: Drs Laskin and Sandler, Part 1 (audio)Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on never-smokers and EGFR mutation testing.2010-01-0510 min
GRACEcast Lung Cancer VideoThought Leader Round Table: Drs Laskin and Sandler, Part 1 (video)Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on never-smokers and EGFR mutation testing.2010-01-0510 minGRACEcast Lung Cancer AudioCancer Lifeline Lecture - Part 3, Locally Advanced, Unresectable NSCLC (audio)This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he covers the optimal treatment strategies for locally advanced (stage III), unresectable NSCLC.2009-09-1113 minGRACEcast Lung Cancer AudioCancer Lifeline Lecture - Part 2, Adjuvant Chemo for Early Stage NSCLC (audio)This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses the evidence supporting the current standard of adjuvant (post-operative) chemotherapy to improve survival for patients with early stage, resected NSCLC.2009-08-2022 minGRACEcast Lung Cancer AudioManagement Options for Stage IIIA NSCLC: The Outer Limits of Resectability (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West covers the most common management strategies for stage IIIA N2 node-positive NSCLC, with a particular focus on a comparison of preoperative treatment followed by surgery vs. chemo and radiation without surgery.2009-07-2009 minGRACEcast Lung Cancer AudioInterview with Dr. Sarita Dubey: Chemotherapy for Early Stage NSCLC (audio)This interview by medical oncologist Dr. Jack West of Dr. Sarita Dubey, medical oncologist at UCSF Cancer Center, covers the evidence and ongoing questions about the role of chemotherapy in early stage NSCLC.2009-07-0215 minGRACEcast Lung Cancer AudioCancer Lifeline Lecture - Part 1 SCLC (audio)This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses current and investigational treatment options for relapsed small cell lung cancer, with a particular focus on amrubicin.2009-06-1710 minGRACEcast Lung Cancer AudioRamalingam on Advanced NSCLC: First Line and Maintenance Therapy (audio)This interview by medical oncologist Dr. Jack West of Dr. Suresh Ramalingam, medical oncologist at Emory University in Atlanta, covers the evolving first line treatment standards of chemotherapy and targeted therapy for the first line treatment, as well as the emerging issue of maintenance therapy after initial treatment of advanced NSCLC.2009-05-2922 minGRACEcast Lung Cancer AudioNever-Smokers with Lung Cancer: A Separate Disease? (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West presents a general background on the distinct demographic, pathologic, molecular, and treatment outcome features seen among never-smokers with lung cancer.2009-05-2110 min
GRACEcast Radiation Oncology VideoInterview with Raditation Oncologist Vivek Mehta: Radiation from Stage I to Stage IV NSCLC (video)This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.2009-05-1323 minGRACEcast Radiation Oncology AudioInterview with Raditation Oncologist Vivek Mehta: Radiation from Stage I to Stage IV NSCLC (audio)This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.2009-05-1323 minGRACEcast Lung Cancer AudioInterview with Raditation Oncologist Vivek Mehta: Radiation from Stage I to Stage IV NSCLC (audio)This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.2009-05-1323 min
GRACEcast Cancer 101 VideoInterview with Dr. David Djang: The Role of PET Scans in Oncology (video)This interview by medical oncologist Dr. Jack West of Dr. David Djang, nuclear medicine expert in Seattle, covers the general principles and clinical utility of PET scans in lung cancer and other aspects of oncology.2009-05-0119 minGRACEcast Cancer 101 AudioInterview with Dr. David Djang; The Role of PET Scans in Oncology (audio)This interview by medical oncologist Dr. Jack West of Dr. David Djang, nuclear medicine expert in Seattle, covers the general principles and clinical utility of PET scans in lung cancer and other aspects of oncology.2009-05-0119 minGRACEcast Lung Cancer AudioTiming of Maintenance/Second Line Chemotherapy in Advanced NSCLC (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the emerging data about the controversial aspects of timing the transition from first line to second line chemotherapy for advanced non-small cell lung cancer (NSCLC).2009-04-3010 minGRACEcast Lung Cancer AudioInterview with Dr. Suresh Ramalingam: Managing Locally Advanced NSCLC (audio)This interview by medical oncologist Dr. Jack West of lung cancer expert Dr. Suresh Ramalingam from Winship Cancer Institute at Emory University reviews recent results and the changing perspective on optimal treatment of stage III, locally advanced non-small cell lung cancer (NSCLC).2009-04-0908 minGRACEcast Lung Cancer AudioChemotherapy for Second Line Treatment of Non-Small Cell Lung Cancer (NSCLC) (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the development of current standards and anticipated benefits vs. risks of second line chemotherapy for advanced non-small cell lung cancer (NSCLC).2009-03-3110 minGRACEcast Lung Cancer AudioInterview with Dr. Antonia Wozniak: Current Best Practices for Small Cell Lung Cancer (audio)This interview by medical oncologist Dr. Jack West of lung cancer expert Toni Wozniak from Karmanos Cancer Institute at Wayne State University covers current standards for optimal management of small cell lung cancer (SCLC).2009-03-1808 minGRACEcast Lung Cancer AudioThe ABC's of BAC (Bronchioloalveolar Carcinoma) (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the unique clinical, imaging, and treatment response features of advanced bronchioloalveolar carcinoma (BAC), a distinct sybtype of lung adenocarcinoma.2009-03-1113 minGRACEcast Lung Cancer AudioAn Introduction to the Pre-Op Workup and Surgical Options in Early Stage NSCLC (audio)This interview by medical oncologist Dr. Jack West of expert thoracic surgeon Eric Vallières covers the basics of the pre-operative work-up and surgical approaches for early stage non-small cell lung cancer (NSCLC).2009-03-0630 minGRACEcast Lung Cancer AudioOptimal Treatment of Unresectable Locally Advanced NSCLC (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.2009-02-2810 minGRACEcast Lung Cancer AudioAntiangiogenesis in First Line NSCLC (audio)This presentation by medical oncologist and lung cancer expert Dr. Jack West introduces the concept of angiogenesis, with a focus on the combination of Avastin (bevacizumab) with chemotherapy for advanced non-small cell lung cancer (NSCLC).2009-01-3009 minGRACEcast Lung Cancer AudioJanessa Laskin Interview (audio)This interview by medical oncologist Dr. Jack West of fellow medical oncologist and lung cancer expert Dr. Janessa Laskin covers the current standards and controversial aspects of post-operative chemotherapy for resected early stage NSCLC.2009-01-2208 min
GRACEcast Radiation Oncology VideoVivek Mehta Interview (video)This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).2009-01-1423 minGRACEcast Radiation Oncology AudioVivek Mehta Interview (audio)This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).2009-01-1423 min
GRACEcast Lung Cancer AudioVivek Mehta Interview (audio)This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).2009-01-1323 minGRACEcast Lung Cancer AudioFirst Line Chemo for Advanced NSCLC (audio)This presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.2009-01-0809 min